International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations

Journal of Clinical Oncology

Volumn 21, Issue 13, 2003, Pages 2600-2608

  Kaufmann, Manfred ^a   Von Minckwitz, Gunter ^b   Smith, Roy ^b   Valero, Vicente ^b   Gianni, Luca ^b   Eiermann, Wolfgang ^b   Howell, Anthony ^b   Dan Costa, Serban ^b   Beuzeboc, Philippe ^b   Untch, Michael ^b   Blohmer, Jens Uwe ^b   Sinn, Hans Peter ^b   Sittek, Rolf ^b   Souchon, Rainer ^b   Tulusan, Augustinos H ^b   Volm, Tanja ^b   Senn, Hans Jörg ^b  

^a GOETHE UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT THERAPY; ADVANCED CANCER; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL SOCIETY; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMIC THERAPY; TREATMENT INDICATION; TUMOR LOCALIZATION; BREAST TUMOR; CANCER STAGING; FEMALE; INTERNATIONAL COOPERATION; PATIENT SELECTION;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INTERNATIONAL COOPERATION; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS;

EID: 0038013982     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.01.136     Document Type: Review

References (53)

1. National Institutes of Health: NIH Consensus Development Conference, Bethesda, 2000. http://consensus.nih.gov
2. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer-Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19:3817-3827, 2001
3. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
4. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
5. Early Breast Cancer Trialists' Collaborative Group: Ovarian ablation in early breast cancer: Overview of the randomised trials. Lancet 348:1189-1196, 1996
6. Fisher B, Redmond C, Poisson R, et al: Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 320:822-828, 1989
7. Simpson-Herren L, Sanford AH, Holmquist JP: Effects of surgery on the cell kinetics of residual tumour. Cancer Treat Rep 60:1749-1760, 1976
8. Ketcham AS, Wexler H, Mantel N: The effect of removal of a "primary" tumor on the development of spontaneous metastases: I. Development of a standardized experimental technique. Cancer Res 19:940-944, 1959
9. Gunduz N, Fisher B, Saffer EA: Effect of surgical removal on the growth and kinetics of residual tumour. Cancer Res 39:3861-3865, 1979
10. Fisher B, Gunduz N, Saffer FA: Influence of the interval between primary tumour removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43:1488-1492, 1983
11. G. Hortobagyi, A. U. Buzdar. Locally advanced breast cancer, in Bonadonna G, Hortobagyi GN, Gianni AM (eds): Textbook of Breast Cancer: A Clinical Guide to Therapy. London, UK, Martin Dunitz Ltd, 1997, pp. 155-168
12. Bonadonna G, Veronesi U, Brambilla C, et al: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539-1545, 1990
13. Jacquillat C, Weil M, Baillet F, et al: Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66:119-129, 1990
14. Anderson ED, Forrest AP, Hawkins RA, et al: Primary systemic therapy for operable breast cancer. Br J Cancer 63:561-566, 1991
15. Smith IE, Jones AL, O'Brien ME, et al: Primary medical (neoadjuvant) chemotherapy for operable breast cancer. Eur J Cancer 29A:1796-1799, 1993
16. Smith IE, Walsh G, Jones A, et al: High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13:424-429, 1995
17. Bonadonna G, Valagussa P, Brambilla C, et al: Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100, 1998
18. Chollet P, Charrier S, Brain E, et al: Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 33:862-866, 1997
19. Calais G, Berger C, Descamps P, et al: Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer 74:1283-1288, 1994
20. Forrest AP, Levack PA, Chetty U, et al: A human tumour model. Lancet 2:840-842, 1986
21. Kaufmann M, Kubli F: Current state of chemosensitivity testing of tumors. Dtsch Med Wochenschr 108:150-154, 1983
22. Jakesz R, for the ABCSG: Comparison of pre- vs. postoperative chemotherapy in breast cancer patients: Four-year results of Austrian Breast & Colorectal Cancer Study Group (ABCSG) Trial 7. Proc Am Soc Clin Oncol 20:125, 2001
23. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997
24. Scholl SM, Fouquet A, Asselain B, et al: Primary versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: Preliminary results of a randomised trial. Eur J Cancer 30A:645-652, 1994
25. van der Hage JA, van de Velde CJH, Julien JP, et al: Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 19:4224-4237, 2001
26. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
27. Pierga JY, Mouret E, Dieras V, et al: Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 83:1480-1487, 2000
28. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
29. Smith IC, Heys SD, Hutcheon AW, et al: Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466, 2002
30. von Minckwitz G, Costa SD, Raab G, et al: Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase IIb study. J Clin Oncol 19:3506-3515, 2001
31. Buzdar AU, Singletary SE, Theriault RL, et al: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17:3412-3417, 1999
32. Penault-Llorca F, Sastre X, Fiche M, et al: Pathological response to neoadjuvant chemotherapy (CT): Final results of a prospective randomized trial of 4AT vs 4AC as induction therapy in patients with operable breast cancer using Sataloff classification. Breast Cane Res Treat 57:67, 1999 (abstr 248)
33. NSABP: The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: Preliminary results of the NSABP Protocol B-27. Breast Cancer Res Treat 69:210, (abstr 5) 2001 (updated with personal communication 2002, 2003)
34. von Minckwitz G, Raab G, Schütte M, et al: Dose-dense versus sequential Adriamycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2, M0): Primary endpoint analysis of the GEPARDUO study. Proc Am Soc Clin Oncol 21:43a, 2003 (abstr 168)
35. Gianni L, Baselga J, Eiermann W, et al: First report of the European Cooperative Trial in Operable Breast Cancer (ECTO): Effects of primary systemic therapy (PST) on local-regional disease. Proc Am Soc Clin Oncol 21:34a, 2002 (abstr 132)
36. Untch M, Konency G, Ditsch N, et al: Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: Results of a randomised AGO study. Proc Am Soc Clin Oncol 21:34a, 2002 (abstr 133)
37. Wolmark N, Wang J, Mamounas E, et al: Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr 30:96-102, 2001
38. Berry DL, Theriault RL, Holmes FA, et al: Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 17:855-861, 1999
39. McIlhenny C, Doughty JC, George WD,: Optimum number of core biopsies for accurate assessment of histological grade in breast cancer. Br J Surg 89:84-85, 2002
40. von Minckwitz G, Raab G, Blohmer JU, et al: Primary chemotherapy adopted on in-vivo chemotherapy in patients with primary breast cancer. The pilot Gepartrio study. Proc Am Soc Clin Oncol 22, 2003 (abstr)
41. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12:1527-1532, 2001
42. Dixon JM, Renshaw L, Bellamy C, et al: The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: A randomized, double-blind, single-center study. Clin Cancer Res 6:2229-2235, 2000
43. Albain KS, Green SJ, Ravdin PM, et al: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 21:37a, 2002 (abstr 143)
44. Rouzier R, Extra JM, Carton M, et al: Primary chemotherapy for operable breast cancer: Incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol 19:3828-3835, 2001
45. Chevallier B, Roche H, Olivier JP, et al: Inflammatory breast cancer: Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16:223-228, 1993
46. Sinn HP, Schmid H, Junkermann H, et al: Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd 54:552-558, 1994
47. Sataloff DM, Mason BA, Prestipino AJ, et al: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg 180:297-306, 1995
48. Singletary E, Allred C, Ashley P, et al: Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J Clin Oncol 20:3628-3636, 2002
49. Recht A, Edge SB, Solin LJ, et al: Postmastectomy radiotherapy: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1539-1569, 2001
50. Early Breast Cancer Trialists' Collaborative Group: Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. Lancet 355:1757-1770, 2000
51. Colleoni M, Nole F, Minchella I, et al: Pre-operative chemotherapy and radiotherapy in breast cancer. Eur J Cancer 34:641-645, 1998
52. Nardone L, Ausili-Cefaro G, Palazzoni G, et al: Preoperative radiotherapy in the conservative treatment for breast cancer. Rays 22:417-424, 1997
53. Ahr A, Karn T, Solbach C, et al: Identification of high risk breast-cancer patients by gene expression profiling. Lancet 359:131-132, 2002